Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

IMJUDO 20 mg/ml concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
tremelimumab
Company:  
AstraZeneca UK Limited See contact details
ATC code: 
L01FX20
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

IMJUDO Patient Card

{healthcare_pro_orange} For Healthcare Professionals
The purpose of the Imjudo Patient Card is to support patients and carers in understanding the risk of immune-mediated adverse reactions (imAR) and helps them recognise, act on and report relevant symptoms.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

AstraZeneca UK Limited
Company image
Address
2 Pancras Square, 8th Floor, London, N1C 4AG, UK
Telephone
+44 (0)1582 836 000
Fax
+44 (0)1582 838 000
Medical Information Direct Line
0800 783 0033
Medical Information e-mail
[email protected]
Medical Information Website
https://medicalinformation.astrazeneca.co.uk/
Medical Information Website
www.myazmed.co.uk